Results 61 to 70 of about 7,464 (222)

Immunocompromised Status Definition in Observational Studies Using Electronic Health Records: A Scoping Review and a Proposal for a Phenotype Identification Algorithm

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Immunocompromised individuals experience an impaired immune function due to conditions that might be either congenital or acquired over the course of their lives. Epidemiological studies often rely on clinical definitions which, in some cases, benefit from being translated into machine‐readable algorithms for application to electronic health ...
Judit Riera‐Arnau, Nicoletta Luxi, Fabio Riefolo, Martín Solorzano, Irene Pazos, Elena Ballarín, Lise Skovgaard Svingel, Lorenzo Chiusaroli, Elisa Martín‐Merino, Elisa Barbieri, María Lopez‐Lasanta, Sima Mohammadi, Denis Rotta, Alexandra Pacurariu, Catherine Cohet, Miriam Sturkenboom, Carlos E. Durán, on behalf of the SAFETY‐VAC study consortium, Carlos E. Durán, Miriam Sturkenboom, Judit Riera‐Arnau, Nicoletta Luxi, Olaf Klungel, Patrick Souverein, Sima Mohammadi, Fabio Riefolo, Irene Pazos, Rosa Gini, Davide Messina, Giuseppe Roberto, Carlo Giaquinto, Elisa Barbieri, Luca Stona, Felipe Villalobos, Martín Solorzano, Carlo Alberto Bissacco, Antonio Gimeno, Beatriz Poblador, Mercedes Aza, Aida Moreno, Alejandro Santos, Vera Ehrenstein, Lise Skovgaard Svingel, Benjamin Randeris Johannesen, Cécile Droz‐Perroteau, Laure Carcaillon‐Bentata, Anna‐Mija Tolppanen, Sirpa Hartikainen, Thuan Vo, Anne Paakinaho, Blair Rajamaki, Hedvig Nordeng, Saeed Hayati, Mahmoud Zidan, Juan José Carreras Martínez, Arantxa Urchueguía Fornes, Elisa Correcher Martínez, Javier Díez‐Domingo, Mar Martin, Patricia Garcia‐Poza, Airam de Burgos, Belén Castillo‐Cano, Elisa Martín‐Merino   +62 more
wiley   +1 more source

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection

HIV/AIDS: Research and Palliative Care, 2016
Rustin D Crutchley,1 Rakesh C Guduru,2 Amy M Cheng1 1Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, 2CompanionDX, Houston, TX, USA Abstract: Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (
Crutchley RD, Guduru RC, Cheng AM,
doaj  

Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis. [PDF]

, 2017
Background Accurately determining renal function is essential for clinical management of HIV patients. Classically, it has been evaluated by estimating glomerular filtration rate (eGFR) with the MDRD-equation, but today there is evidence that the new ...
Agüero Santangelo, Fernando, Bedini, J. L., Cofán Pujol, Federico, Cristelli, M. P., Manzardo, Christian, Miró Meda, José M., Moreno Camacho, Ma. Asunción, Oppenheimer Salinas, Federico, Rico, N., Trullás Vila, Joan Carles   +9 more
core   +1 more source

Development and Validation of a Simple and Robust Bioanalytical Method for Simultaneous Quantification of Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Human Plasma Using LC–MS/MS and Its Application in a Pharmacokinetic Study

SEPARATION SCIENCE PLUS, Volume 9, Issue 4, April 2026.
ABSTRACT A simple, sensitive, and selective LC–MS/MS method has been developed and validated, in accordance with ICH M10 guidelines, for the simultaneous quantification of Bictegravir (BTV), Emtricitabine (ECB), and Tenofovir alafenamide (TAM) in human plasma.
Boosi Ravi Kumar, Muvvala Venkatanarayana, Shiva Kumar Koppula, Valluru Rajani Kumar   +3 more
wiley   +1 more source

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1-Infected Patients: Week 48 Results [PDF]

, 2017
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind, double-dummy, active-controlled trial was conducted to evaluate the efficacy and safety of COBI versus ...
Andrade-Villanueva, Jaime, Antunes, Francisco, Arastéh, Keikawus, Callebaut, Christian, Cheng, Andrew K., Chetchotisakd, Ploenchan, DeJesus, Edwin, Fehr, Jan, Gallant, Joel E., Koenig, Ellen, Liu, Yapei, Moyle, Graeme, Rhee, Martin S., Rizzardini, Giuliano, Szwarcberg, Javier, Zhong, Lijie   +15 more
core  

Risk factors contributing to a low darunavir plasma concentration [PDF]

, 2017
Darunavir is an efficacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to find predisposing factors for low darunavir plasma concentrations in patients starting the once- or twice-daily dosage. Darunavir
Alffenaar, Jan Willem C., Bierman, Wouter F.W., Daskapan, Alper, Kosterink, Jos G.W., Stienstra, Ymkje, Touw, Daan J., van der Werf, Tjip S.   +6 more
core   +2 more sources

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, Volume 27, Issue 4, Page 572-584, April 2026.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source

Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. [PDF]

, 2019
Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of ...
Chan, Alexandre, Klibanov, Olga, Olin, Jacqueline L, Spooner, Linda M   +3 more
core   +1 more source

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir [PDF]

, 2016
OBJECTIVE: Atazanavir (ATV) and lopinavir (LPV) have been associated with kidney disease progression in HIV positive patients, with no data reported for darunavir (DRV).
Chadwick, D, Hamzah, L, Jones, R, Jose, S, Nelson, M, Phillips, A, Post, FA, Sabin, CA, Trevelion, R, Williams, DI   +9 more
core   +2 more sources

Comparative effectiveness of dolutegravir + lamivudine versus three‐drug regimens in Swedish clinical practice: a nationwide study

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction HIV guidelines recommend switching from a three‐drug regimen (3DR) to dolutegravir + lamivudine (DTG+3TC) for eligible individuals. This retrospective national cohort study used Swedish InfCareHIV registry data to evaluate long‐term outcomes of adults with HIV RNA <50 copies/ml who switched to DTG+3TC or a guideline‐recommended ...
Erik Sörstedt, George Nduva, Fredrik Månsson, Åsa Mellgren, Johanna Repits, Eva Fernvik, Adam Stubbs, Melanie Schroeder, Johanna Brännström, Christina Carlander   +9 more
wiley   +1 more source